J&J and Pfizer Among BlackRock Fund Advisors’ Top Healthcare Stock Holdings

Wall St. Watchdog reveals information regarding BlackRock Fund Advisors’ top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 426 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $16.655 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, BlackRock Fund Advisors reported holding 21,241,820 shares with a market value of $1,413,005,795. This comprised 0.68% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 21,635,201 shares with a market value of $1,377,945,922. This comprised 0.83% of the total portfolio. The net change in shares for this position over the two quarters is 393,381. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, BlackRock Fund Advisors reported holding 60,795,150 shares with a market value of $1,252,380,113. This comprised 0.61% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 61,959,190 shares with a market value of $1,095,438,498. This comprised 0.66% of the total portfolio. The net change in shares for this position over the two quarters is 1,164,040. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, BlackRock Fund Advisors reported holding 26,250,235 shares with a market value of $926,370,817. This comprised 0.45% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 27,004,804 shares with a market value of $883,057,111. This comprised 0.53% of the total portfolio. The net change in shares for this position over the two quarters is 754,569. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, BlackRock Fund Advisors reported holding 12,518,441 shares with a market value of $658,720,352. This comprised 0.32% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 13,044,961 shares with a market value of $667,119,298. This comprised 0.4% of the total portfolio. The net change in shares for this position over the two quarters is 526,520. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, BlackRock Fund Advisors reported holding 16,458,351 shares with a market value of $476,633,830. This comprised 0.23% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 16,213,760 shares with a market value of $508,787,775. This comprised 0.31% of the total portfolio. The net change in shares for this position over the two quarters is -244,591. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, BlackRock Fund Advisors reported holding 9,234,329 shares with a market value of $538,823,083. This comprised 0.26% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 8,744,332 shares with a market value of $480,588,479. This comprised 0.29% of the total portfolio. The net change in shares for this position over the two quarters is -489,997. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, BlackRock Fund Advisors reported holding 9,916,277 shares with a market value of $372,157,864. This comprised 0.18% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 10,973,982 shares with a market value of $405,708,128. This comprised 0.24% of the total portfolio. The net change in shares for this position over the two quarters is 1,057,705. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, BlackRock Fund Advisors reported holding 8,688,083 shares with a market value of $448,131,337. This comprised 0.22% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 8,112,181 shares with a market value of $374,133,779. This comprised 0.23% of the total portfolio. The net change in shares for this position over the two quarters is -575,902. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Medtronic Inc. (NYSE:MDT): On 06/30/2011, BlackRock Fund Advisors reported holding 9,525,340 shares with a market value of $367,011,339. This comprised 0.18% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 9,659,604 shares with a market value of $321,085,253. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is 134,264. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011, BlackRock Fund Advisors reported holding 8,110,605 shares with a market value of $335,860,152. This comprised 0.16% of the total portfolio. On 09/30/2011, BlackRock Fund Advisors reported holding 7,810,636 shares with a market value of $303,052,671. This comprised 0.18% of the total portfolio. The net change in shares for this position over the two quarters is -299,969. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

(Note: Data regarding BlackRock Fund Advisors’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet